ARCT vs QSI

Key Takeaways

• ARCT and QSI are both early-stage life sciences companies trading at depressed levels, with ARCT around $5.76 and QSI near $0.78 as of late July 2026.
• Arcturus Therapeutics recently secured a strategic manufacturing collaboration with Thermo Fisher Scientific, a meaningful catalyst for its lead cystic fibrosis program ARCT-032.
• Quantum-Si faces a Nasdaq minimum bid price compliance challenge, having received a delisting warning in late July 2026 after its stock traded below $1 for 30 consecutive business days.
• Both companies are burning cash and generating minimal revenue, but ARCT has a more advanced clinical pipeline while QSI is pre-revenue in a commercial sense, guiding for only ~$1 million in 2026 revenue.
• ARCT's revenue has contracted sharply (down 93% year-over-year in Q1 2026), while QSI is navigating a deliberate "transition year" ahead of its Proteus platform launch.
• Wall Street analysts maintain "Buy" ratings on both stocks, but the risk profiles differ markedly given QSI's exchange compliance issues and ARCT's clinical binary risk.

Introduction

Comparing ARCT and QSI places two biotechnology-adjacent innovators under the same lens — one focused on messenger RNA (mRNA) therapeutics for rare diseases, the other on next-generation protein sequencing (NGPS) technology. Both companies operate at the frontier of molecular biology, yet they face starkly different near-term challenges. ARCT is navigating a steep revenue decline as legacy COVID-era contracts wind down, while QSI is fighting to maintain its Nasdaq listing. This stock comparison is most relevant for traders and investors with a high risk tolerance who are evaluating speculative life sciences names at depressed valuations.

ARCT Overview and Recent Performance

ARCT, or Arcturus Therapeutics Holdings Inc., is a San Diego-based mRNA medicines company developing therapeutics for liver and respiratory rare diseases. Its proprietary platforms — LUNAR (lipid-mediated delivery) and STARR (self-amplifying mRNA technology) — underpin a pipeline that includes ARCT-032 for cystic fibrosis (Phase 2) and ARCT-810 for ornithine transcarbamylase (OTC) deficiency (Phase 2). Arcturus also developed KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine, in partnership with CSL Seqirus.

In recent weeks, ARCT stock has traded near the lower end of its 52-week range of $5.50 to $24.17, with a market capitalization of approximately $164 million. The stock's decline reflects a sharp contraction in revenue: full-year 2025 revenue fell 46% to $82 million, and Q1 2026 revenue plummeted 93% year-over-year to just $2.1 million as pandemic-era manufacturing contracts expired. Net losses have persisted, with the company reporting a net loss of $65.8 million in 2025.

The most significant recent development came in early July 2026, when Arcturus announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032. Under the agreement, Thermo Fisher will provide integrated manufacturing, clinical research, and commercial readiness services. This partnership — involving a world-class contract development and manufacturing organization (CDMO, a company that provides drug development and manufacturing services) — signals growing institutional confidence in the cystic fibrosis program and provides a concrete catalyst for the stock.

QSI Overview and Recent Performance

QSI, or Quantum-Si Incorporated, is a Branford, Connecticut-based proteomics technology company that has developed a proprietary single-molecule detection platform for next-generation protein sequencing. Founded by serial entrepreneur Jonathan Rothberg, the company went public in 2021 via a special purpose acquisition company (SPAC) merger valued at $1.46 billion. Its commercial products include the Platinum and Platinum Pro NGPS instruments, with the next-generation Proteus platform — a higher-throughput, more automated system — slated for commercial launch by late 2026.

QSI stock has been under severe pressure in recent months, trading around $0.78 with a market cap near $171 million. The 52-week range spans $0.69 to $3.10. In late July 2026, Quantum-Si disclosed that Nasdaq had issued a delisting warning after the stock closed below $1 for 30 consecutive business days. The company has until January 2027 to regain compliance. This is the second such warning in less than two years; the first, in November 2024, was resolved within weeks.

Revenue remains minimal — approximately $2.4 million for full-year 2025 and just $258,000 in Q1 2026 — as the company deliberately prioritizes Proteus development over near-term instrument sales. Management has characterized 2026 as a "transition year," guiding for full-year revenue of approximately $1 million. On the positive side, Quantum-Si held $190 million in cash and investments as of March 2026, with a projected runway into the second quarter of 2028. The Proteus platform has generated encouraging early customer feedback, with successful sample sequencing runs completed on prototype units.

Trending AI Robots

In a market environment where volatility and sentiment shifts can reshape stock trajectories overnight, many traders are turning to automated tools for data-driven decision support. Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing AI trading bots, drawn from a pool of hundreds that collectively trade thousands of different tickers. Only the bots best suited to current market conditions earn a place in this featured section. These AI-driven systems span a wide range of trading styles and strategies — from swing trading to trend following — each with its own performance metrics, statistical profile, and preferred basket of securities. Traders can explore bots with varying win rates, Sharpe ratios, and trade frequencies, all backed by real-time market data. To explore which AI trading strategies are resonating in today's market, visit the Trending AI Robots page.

Head-to-Head Comparison

Despite both being classified within the broad biotechnology and life sciences universe, ARCT and QSI operate fundamentally different business models. ARCT is a clinical-stage drug developer whose value hinges on binary outcomes from clinical trials and regulatory approvals. Its revenue stream, while currently contracting, has historically included substantial collaboration and grant income from partners such as CSL Seqirus and BARDA (the U.S. Biomedical Advanced Research and Development Authority). QSI, by contrast, is a life sciences tools company attempting to commercialize a disruptive instrument platform — its revenue must be built instrument by instrument, consumable kit by consumable kit.

Growth drivers: ARCT's near-term catalyst is the Thermo Fisher collaboration and progress toward Phase 3 for ARCT-032. QSI's entire thesis rests on the successful commercial launch of Proteus by late 2026. If Proteus delivers on its technical promise, it could open a substantial total addressable market in proteomics; if it stalls, QSI's path to meaningful revenue becomes uncertain.

Risk factors: QSI faces an immediate existential concern with the Nasdaq delisting notice. A reverse stock split or sustained price recovery would be required to regain compliance. ARCT faces the standard biotech risk of clinical failure, compounded by a rapidly shrinking revenue base and a cash position that will need reinforcement if pivotal trials extend.

Market sentiment: Both stocks carry high beta — ARCT at 2.36 and QSI near 2.22 — indicating amplified sensitivity to broader market moves. Wall Street analysts maintain "Buy" ratings on both, but ARCT enjoys coverage from 13 analysts with a consensus price target of $20.60 (implying roughly 258% upside), while QSI's 3 covering analysts target $2.50 (approximately 219% upside). The wide discrepancy between current prices and analyst targets reflects the high-risk, high-reward nature of both names.

Sector exposure: ARCT is tied to the mRNA therapeutic revolution, which gained prominence during the pandemic but now faces investor skepticism about commercial sustainability. QSI is positioned in the proteomics tools market, a space with significant long-term scientific potential but limited near-term commercial validation.

Tickeron AI Verdict

Based on observable trend consistency, catalyst quality, and relative risk positioning, Tickeron's AI analytical framework would likely lean toward ARCT in the current environment. The Thermo Fisher collaboration announced in early July represents a tangible, institutionally validated catalyst that reduces manufacturing risk for the lead pipeline program. While both companies face significant fundamental headwinds — ARCT's eroding revenue and QSI's delisting risk — ARCT's clinical pipeline is further along the value-creation curve, and the company is not confronting an immediate exchange compliance crisis. That said, the AI's preference is probabilistic rather than absolute; QSI's Proteus platform, if executed successfully, could dramatically reshape the company's trajectory. Traders should weigh ARCT's nearer-term catalyst visibility against QSI's higher-risk, potentially higher-reward technology platform depending on their individual strategy and risk profile.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations